ARCT
USDArcturus Therapeutics Holdings Inc. Common Stock
Precio en Tiempo Real
Gráfico de Precios
Métricas Clave
Métricas de Mercado
Apertura
$9.170
Máximo
$9.400
Mínimo
$8.840
Volumen
1.18M
Fundamentos de la Empresa
Capitalización de Mercado
242.5M
Industria
Biotecnología
País
United States
Estadísticas de Negociación
Volumen Promedio
1.22M
Bolsa
NGM
Moneda
USD
Rango de 52 Semanas
Noticias Relacionadas
HC Wainwright & Co. Downgrades Arcturus Therapeutics to Neutral, Lowers Price Target to $12
HC Wainwright & Co. analyst Andrew S. Fein downgrades Arcturus Therapeutics from Buy to Neutral and lowers the price target from $60 to $12.
Citigroup Downgrades Arcturus Therapeutics to Neutral, Lowers Price Target to $12
Citigroup analyst Yigal Nochomovitz downgrades Arcturus Therapeutics from Buy to Neutral and lowers the price target from $49 to $12.
Arcturus' Investigational Inhaled Therapy Lacks Meaningful Lung Function Improvement, Analyst Notes Mixed Picture
Arcturus stock drops on interim Phase 2 results for ARCT-032, showing promising mucus reduction in cystic fibrosis patients but no initial FEV₁ improvement.
BTIG Maintains Buy on Arcturus Therapeutics, Lowers Price Target to $23
BTIG analyst Thomas Shrader maintains Arcturus Therapeutics with a Buy and lowers the price target from $48 to $23.
Guggenheim Downgrades Arcturus Therapeutics to Neutral
Guggenheim analyst Seamus Fernandez downgrades Arcturus Therapeutics from Buy to Neutral.
Arcturus Therapeutics Provides Interim Phase 2 Data for Cystic Fibrosis (CF) Program
ARCT-032 generally safe and well tolerated Meaningful trends of clinical activity observed via high resolution CT scans After only 28 days of treatment with ARCT-032 (10 mg), 4 out of 6 Class I CF participants
Acciones Relacionadas
Mantente Actualizado
Configura alertas de precio, recibe actualizaciones de análisis de IA y noticias de mercado en tiempo real.